JP7638915B2 - ロイコメチルチオニニウムの治療上の相互作用 - Google Patents

ロイコメチルチオニニウムの治療上の相互作用 Download PDF

Info

Publication number
JP7638915B2
JP7638915B2 JP2021577641A JP2021577641A JP7638915B2 JP 7638915 B2 JP7638915 B2 JP 7638915B2 JP 2021577641 A JP2021577641 A JP 2021577641A JP 2021577641 A JP2021577641 A JP 2021577641A JP 7638915 B2 JP7638915 B2 JP 7638915B2
Authority
JP
Japan
Prior art keywords
treatment
compound
therapeutic composition
lmtx
neurotransmission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021577641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538642A5 (enExample
JP2022538642A (ja
Inventor
ロバート ハリントン，チャールズ
リーデル，ゲルノット
メリス，ヴァレリア
クライン，ヨヘン
ニエヴィアドムスカ，グラジーナ
ステチュコフスカ，マルタ
シュワブ，カリマ
ミシェル ウィスチク，クロード
Original Assignee
ウィスタ ラボラトリーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスタ ラボラトリーズ リミテッド filed Critical ウィスタ ラボラトリーズ リミテッド
Publication of JP2022538642A publication Critical patent/JP2022538642A/ja
Publication of JP2022538642A5 publication Critical patent/JP2022538642A5/ja
Application granted granted Critical
Publication of JP7638915B2 publication Critical patent/JP7638915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Steroid Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
JP2021577641A 2019-07-01 2020-06-30 ロイコメチルチオニニウムの治療上の相互作用 Active JP7638915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909493.7 2019-07-01
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Publications (3)

Publication Number Publication Date
JP2022538642A JP2022538642A (ja) 2022-09-05
JP2022538642A5 JP2022538642A5 (enExample) 2023-07-10
JP7638915B2 true JP7638915B2 (ja) 2025-03-04

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577641A Active JP7638915B2 (ja) 2019-07-01 2020-06-30 ロイコメチルチオニニウムの治療上の相互作用

Country Status (12)

Country Link
US (1) US20230031369A1 (enExample)
EP (1) EP3989954A1 (enExample)
JP (1) JP7638915B2 (enExample)
KR (1) KR20220027203A (enExample)
CN (1) CN114126622A (enExample)
AU (1) AU2020298758B2 (enExample)
BR (1) BR112021025256A2 (enExample)
CA (1) CA3143790A1 (enExample)
GB (1) GB201909493D0 (enExample)
IL (1) IL289338B2 (enExample)
MX (1) MX2021015292A (enExample)
WO (1) WO2021001380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
GB202500018D0 (en) * 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia
WO2020020751A1 (en) 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018019823A1 (en) 2016-07-25 2018-02-01 Wista Laboratories Ltd. Administration and dosage of diaminophenothiazines
WO2018041739A1 (en) 2016-09-01 2018-03-08 Wista Laboratories Ltd. Treatment of dementia
WO2020020751A1 (en) 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Also Published As

Publication number Publication date
WO2021001380A1 (en) 2021-01-07
US20230031369A1 (en) 2023-02-02
GB201909493D0 (en) 2019-08-14
IL289338B2 (en) 2026-07-01
AU2020298758A1 (en) 2022-02-24
CA3143790A1 (en) 2021-01-07
IL289338B1 (en) 2026-03-01
EP3989954A1 (en) 2022-05-04
IL289338A (en) 2022-02-01
JP2022538642A (ja) 2022-09-05
BR112021025256A2 (pt) 2022-01-25
MX2021015292A (es) 2022-01-18
AU2020298758B2 (en) 2026-07-30
KR20220027203A (ko) 2022-03-07
CN114126622A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
Moavero et al. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy
US11123332B2 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
US20180311217A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
JP2019526571A (ja) 認知症の処置
US20190247379A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
JP2022538642A (ja) ロイコメチルチオニニウムの治療上の相互作用
US20190030035A1 (en) Compositions and methods for treating dementia
KR20190006515A (ko) App 의 정상 가공을 촉진하는 화합물
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
AU2024231880A1 (en) Diaminophenothiazine for the treatment of microvascular brain disease disease
US20120289556A1 (en) Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia
Ligsay et al. Overview of targeted double-blind, placebo-controlled clinical trials in fragile X syndrome
Shua-Haim et al. Current and the near future medications for Alzheimer's disease: What can we expect from them?
KR20160085757A (ko) 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료
CA3193824A1 (en) Riluzole for the treatment of alzheimer's disease
Stock Efficacy and tolerability of long-term (up to 5 years) open-label treatment with aripiprazole in schizophrenia
FI et al. PUBLIC ASSESSMENT REPORT

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250219

R150 Certificate of patent or registration of utility model

Ref document number: 7638915

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150